首页> The Lancet. Infectious diseases> Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial.

Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial.

导出 LinkOut

翻译打印收藏纠错

第一作者： Aitana,Juan-Giner

第一单位： Epicentre, Paris, France.

作者： Aitana,Juan-Giner ^[1] ; Maria L,Namulwana ^[2] ; Derick,Kimathi ^[3] ; Kyra H,Grantz ^[4] ; Gamou,Fall ^[5] ; Moussa,Dia ^[5] ; Ndeye S,Bob ^[5] ; Amadou Alpha,Sall ^[5] ; Caroline,Nerima ^[2] ; Mateus Kambale,Sahani ^[2] ; Edgar M,Mulogo ^[6] ; Immaculate,Ampeire ^[7] ; Joachim,Hombach ^[8] ; Deborah,Nanjebe ^[2] ; Juliet,Mwanga-Amumpaire ^[2] ; Derek A T,Cummings ^[9] ; Philip,Bejon ^[3] ; George M,Warimwe ^[3] ; Rebecca F,Grais ^[10]

作者单位： Epicentre, Paris, France. ^[1] Epicentre Mbarara Research Centre, Mbarara, Uganda. ^[2] Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya; Centre for Tropical Medicine & Global Health, University of Oxford, Oxford, UK. ^[3] Department of Biology and Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. ^[4] Institut Pasteur Dakar, Dakar, Senegal. ^[5] Department of Community Health, Mbarara University of Science & Technology, Mbarara, Uganda. ^[6] Expanded Program on Immunization, Ministry of Health, Kampala, Uganda. ^[7] Immunization, Vaccines, and Biologicals, World Health Organization, Geneva, Switzerland. ^[8] Department of Biology and Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA. ^[9] Epicentre, Paris, France. Electronic address: rebecca.grais@epicentre.msf.org. ^[10]